Y-mAbs to Participate in Upcoming Investor Conferences in October
Insiders At Y-mAbs Therapeutics Sold US$4.5m In Stock, Alluding To Potential Weakness
While Shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
Express News | Wedbush Reiterates Outperform on Y-mAbs Therapeutics, Maintains $23 Price Target
Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study
Express News | Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Y-mAbs to Participate in Upcoming Investor Conferences in September
The 21% Return This Week Takes Y-mAbs Therapeutics' (NASDAQ:YMAB) Shareholders One-year Gains to 178%
Y-mAbs Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $20
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Express News | Y-mAbs Therapeutics Shares Are Trading. The Stock May Be Rebounding After Falling Earlier in the Week on Weak Earnings and Guidance
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
Y-mAbs Therapeutics Is Maintained at Underweight by Morgan Stanley
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26
Express News | Y-mAbs Therapeutics Inc. : Morgan Stanley Cuts Target Price to $11.00 From $12.00